{
  "success": true,
  "pagesUsed": [
    2,
    3,
    4,
    5,
    6,
    7,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    19,
    20,
    21,
    22,
    24,
    25,
    26,
    27,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48
  ],
  "modelUsed": "gpt-5.2",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "ALXN1840",
        "type": {
          "id": "a0778e3f-cf94-4d1d-9955-538d446c8c12",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "a03d0fbd-aff6-4a38-81b7-0afebe6c437e",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Oral bis-choline tetrathiomolybdate (formerly WTX101), a copper binding agent for Wilson disease; administered as repeat-dose 15 mg/day with planned titration to 30 mg/day.",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Penicillamine",
        "type": {
          "id": "9957e28e-1952-42e6-a847-93473ea2dd58",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "751f7552-a834-4109-bc6b-903ce9da02ef",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Wilson disease copper-chelating therapy; participants taking it at enrollment must discontinue starting Day -4 to allow baseline copper/molybdenum balance assessment.",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Trientine",
        "type": {
          "id": "58167937-5ab1-4950-a7cc-36fb798f5757",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "8ecbf50b-0470-4164-8bbc-81833ae055de",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Wilson disease copper-chelating therapy; participants taking it at enrollment must discontinue starting Day -4 to allow baseline copper/molybdenum balance assessment.",
        "productIds": [
          "prod_3"
        ],
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Zinc therapy",
        "type": {
          "id": "e1c452ad-1603-4a1a-856b-1ee8539967a4",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "9ff4b709-a76b-4199-ac09-4c43d9d8e576",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Wilson disease therapy affecting intestinal copper absorption; must be discontinued and participants must be off zinc for a minimum of 21 days prior to Day 1.",
        "productIds": [
          "prod_4"
        ],
        "administrationIds": [
          "admin_4"
        ]
      },
      {
        "id": "int_5",
        "name": "Acetaminophen (paracetamol)",
        "type": {
          "id": "0662fd39-3f97-4ef5-a58d-c2f22342e911",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "4ab2fd42-f09c-4a4d-90fd-150d6e8ae13e",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted concomitant medication with Investigator approval; maximum 1000 mg/day.",
        "productIds": [
          "prod_5"
        ],
        "administrationIds": [
          "admin_5"
        ]
      },
      {
        "id": "int_6",
        "name": "Ibuprofen",
        "type": {
          "id": "07fe238a-ac68-4572-be31-05d1767e3877",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "006345aa-e48a-42ba-9c6b-bd7f677f74cb",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted concomitant medication with Investigator approval; use with caution; maximum 1200 mg in any 24-hour period.",
        "productIds": [
          "prod_6"
        ],
        "administrationIds": [
          "admin_6"
        ]
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "ALXN1840 tablets (formerly WTX101)",
        "administrableDoseForm": {
          "id": "4848b2fb-3a50-4cad-bfea-c3edc768fd9c",
          "code": "C42998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Tablet",
          "standardCode": {
            "id": "d5518834-ae2a-4def-8897-6a7762d55209",
            "code": "C42998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Tablet",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "00e30f78-4cc0-4ec9-8d2c-4f9341eb71fb",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "15 mg ALXN1840 (containing 7.8 mg tetrathiomolybdic acid)",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Alexion"
      },
      {
        "id": "prod_2",
        "name": "Penicillamine",
        "administrableDoseForm": {
          "id": "6cf4f989-05ff-4bc4-a82a-15ae33929c8a",
          "code": "C17998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Unknown",
          "standardCode": {
            "id": "18ec513b-f3f9-4d8f-824e-e86627188a81",
            "code": "C17998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Unknown",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "c8dacf94-19b1-4263-a36e-8831d2ccc738",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "substanceIds": [
          "sub_2"
        ]
      },
      {
        "id": "prod_3",
        "name": "Trientine",
        "administrableDoseForm": {
          "id": "070cedc5-9166-4753-b37c-ae8d065327a6",
          "code": "C17998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Unknown",
          "standardCode": {
            "id": "9cc9cada-5292-43ae-89b9-4c088b514135",
            "code": "C17998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Unknown",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "f6d23c35-2dfc-472d-bf04-4a0d4396255e",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "substanceIds": [
          "sub_3"
        ]
      },
      {
        "id": "prod_4",
        "name": "Zinc therapy",
        "administrableDoseForm": {
          "id": "91276888-9524-4235-a5f4-a0bb111bf68c",
          "code": "C17998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Unknown",
          "standardCode": {
            "id": "3c2ca3d9-b29a-499e-a91d-eafda09e265b",
            "code": "C17998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Unknown",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "4fb8bdf3-170d-4a96-b55f-718f1ba8d33c",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "substanceIds": [
          "sub_4"
        ]
      },
      {
        "id": "prod_5",
        "name": "Acetaminophen (paracetamol)",
        "administrableDoseForm": {
          "id": "12f7fc7e-3b49-4d31-b664-e728c8924e1f",
          "code": "C17998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Unknown",
          "standardCode": {
            "id": "dc5fa3a1-b50d-4e23-9466-5c12829533b2",
            "code": "C17998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Unknown",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "0412ed44-b554-472a-beb9-7c5d2586b903",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "substanceIds": [
          "sub_5"
        ]
      },
      {
        "id": "prod_6",
        "name": "Ibuprofen",
        "administrableDoseForm": {
          "id": "e7570558-4c26-4dea-86a9-2340f0a94906",
          "code": "C17998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Unknown",
          "standardCode": {
            "id": "70da3951-7709-4987-9f80-645af97221de",
            "code": "C17998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Unknown",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "105a652b-36b4-4b72-8a06-af437791c03c",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "substanceIds": [
          "sub_6"
        ]
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "ALXN1840 15 mg/day (Treatment Period 1)",
        "instanceType": "Administration",
        "dose": "15 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Day 1 through Day 28 (approximately 28 days; minimum 4 weeks planned)"
      },
      {
        "id": "admin_2",
        "name": "ALXN1840 30 mg/day (after titration)",
        "instanceType": "Administration",
        "dose": "30 mg (administered as 2 × 15 mg tablets)",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Day 29 through Day 39 (approximately 11 days)"
      },
      {
        "id": "admin_3",
        "name": "ALXN1840 repeat dosing overall",
        "instanceType": "Administration",
        "dose": "15 mg/day or 30 mg/day",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Up to 40 days total dosing per Table 6; participants discontinued from ALXN1840 by their physician at the latest by Day 54 follow-up"
      },
      {
        "id": "admin_4",
        "name": "ALXN1840 administration conditions (inpatient/CRU)",
        "instanceType": "Administration",
        "doseFrequency": "once daily (same time every morning)",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "While in CRU during dosing periods (inpatient periods)"
      },
      {
        "id": "admin_5",
        "name": "ALXN1840 administration conditions (outpatient)",
        "instanceType": "Administration",
        "doseFrequency": "once daily at approximately the same time (±1 hour)",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "During Outpatient Period (Day 9 to Day 23; may be extended up to additional 14 days with Investigator approval)"
      },
      {
        "id": "admin_6",
        "name": "ALXN1840 dose reduction / rechallenge for ALT elevation",
        "instanceType": "Administration",
        "dose": "15 mg every other day (QOD)",
        "doseFrequency": "every other day",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "When ALT returns to <2×ULN (if baseline normal) or <2× increase from baseline (if baseline above reference range) after temporary interruption"
      },
      {
        "id": "admin_7",
        "name": "ALXN1840 dose reduction for ALT increase >2× baseline or >2×ULN",
        "instanceType": "Administration",
        "dose": "Reduce to previous dose level or to 15 mg every other day if on 15 mg once daily",
        "doseFrequency": "every other day (if reduced to 15 mg QOD)",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Until resolution of abnormality; no further dose increase until resolution"
      },
      {
        "id": "admin_8",
        "name": "ALXN1840 dose modification for anemia (hemoglobin <8 g/dL without bleeding)",
        "instanceType": "Administration",
        "dose": "15 mg every other day (QOD) after interruption",
        "doseFrequency": "every other day",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "After temporary interruption; rechallenge when hemoglobin and other hematology parameters return to baseline"
      },
      {
        "id": "admin_9",
        "name": "ALXN1840 dose modification for hemoglobin decrease >30% from baseline",
        "instanceType": "Administration",
        "dose": "Reduce to previous dose level or to 15 mg every other day if on 15 mg once daily",
        "doseFrequency": "every other day (if reduced to 15 mg QOD)",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Until resolution of abnormality; no further dose increase until resolution"
      },
      {
        "id": "admin_10",
        "name": "ALXN1840 dose modification for thrombocytopenia (platelets <30,000/µL)",
        "instanceType": "Administration",
        "dose": "15 mg every other day (QOD) after interruption",
        "doseFrequency": "every other day",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "After temporary interruption; rechallenge when platelets and other hematology parameters return to baseline"
      },
      {
        "id": "admin_11",
        "name": "ALXN1840 dose modification for platelets decrease >30% from baseline (baseline low)",
        "instanceType": "Administration",
        "dose": "Reduce to previous dose level or to 15 mg every other day if on 15 mg once daily",
        "doseFrequency": "every other day (if reduced to 15 mg QOD)",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Until resolution of abnormality; no further dose increase until resolution"
      },
      {
        "id": "admin_12",
        "name": "ALXN1840 dose modification for neutropenia (neutrophils <1.0 × 10^3/µL)",
        "instanceType": "Administration",
        "dose": "15 mg every other day (QOD) after interruption",
        "doseFrequency": "every other day",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "After temporary interruption; rechallenge when neutrophils and other hematology parameters return to baseline"
      },
      {
        "id": "admin_13",
        "name": "Penicillamine discontinuation for baseline assessment",
        "instanceType": "Administration",
        "duration": "If taking at enrollment, discontinue starting Day -4 (approximately 4 days prior to initiating ALXN1840 on Day 1)"
      },
      {
        "id": "admin_14",
        "name": "Trientine discontinuation for baseline assessment",
        "instanceType": "Administration",
        "duration": "If taking at enrollment, discontinue starting Day -4 (approximately 4 days prior to initiating ALXN1840 on Day 1)"
      },
      {
        "id": "admin_15",
        "name": "Zinc therapy washout",
        "instanceType": "Administration",
        "duration": "Must be off zinc therapy for a minimum of 21 days prior to Day 1"
      },
      {
        "id": "admin_16",
        "name": "Acetaminophen (paracetamol) permitted use",
        "instanceType": "Administration",
        "dose": "Up to 1000 mg/day",
        "duration": "As needed during study with Investigator approval"
      },
      {
        "id": "admin_17",
        "name": "Ibuprofen permitted use",
        "instanceType": "Administration",
        "dose": "Up to 1200 mg per 24-hour period",
        "duration": "As needed during study with Investigator approval"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "bis-choline tetrathiomolybdate",
        "instanceType": "Substance",
        "description": "Active substance / drug name for ALXN1840; formerly known as WTX101."
      },
      {
        "id": "sub_2",
        "name": "tetrathiomolybdate (active anion)",
        "instanceType": "Substance",
        "description": "Active anion contained in ALXN1840; rapidly binds copper to form tetrathiomolybdate-copper-albumin complex (TPC)."
      },
      {
        "id": "sub_3",
        "name": "tetrathiomolybdic acid",
        "instanceType": "Substance",
        "description": "Amount specified per tablet: 7.8 mg tetrathiomolybdic acid per 15 mg ALXN1840 tablet."
      },
      {
        "id": "sub_4",
        "name": "penicillamine",
        "instanceType": "Substance",
        "description": "Copper-chelating therapy referenced as prior/concomitant WD therapy; discontinued for baseline assessments if used at enrollment."
      },
      {
        "id": "sub_5",
        "name": "trientine",
        "instanceType": "Substance",
        "description": "Copper-chelating therapy referenced as prior/concomitant WD therapy; discontinued for baseline assessments if used at enrollment."
      },
      {
        "id": "sub_6",
        "name": "zinc",
        "instanceType": "Substance",
        "description": "WD therapy; must be discontinued with minimum 21-day washout before Day 1."
      },
      {
        "id": "sub_7",
        "name": "acetaminophen",
        "instanceType": "Substance",
        "description": "Allowed concomitant medication with maximum 1000 mg/day."
      },
      {
        "id": "sub_8",
        "name": "ibuprofen",
        "instanceType": "Substance",
        "description": "Allowed concomitant medication with maximum 1200 mg per 24 hours; caution advised due to CYP2C9 substrate considerations."
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 6,
      "productCount": 6,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "ALXN1840",
        "role": "Investigational Product",
        "description": "Oral bis-choline tetrathiomolybdate (formerly WTX101), a copper binding agent for Wilson disease; administered as repeat-dose 15 mg/day with planned titration to 30 mg/day."
      },
      {
        "name": "Penicillamine",
        "role": "Concomitant Medication",
        "description": "Wilson disease copper-chelating therapy; participants taking it at enrollment must discontinue starting Day -4 to allow baseline copper/molybdenum balance assessment."
      },
      {
        "name": "Trientine",
        "role": "Concomitant Medication",
        "description": "Wilson disease copper-chelating therapy; participants taking it at enrollment must discontinue starting Day -4 to allow baseline copper/molybdenum balance assessment."
      },
      {
        "name": "Zinc therapy",
        "role": "Concomitant Medication",
        "description": "Wilson disease therapy affecting intestinal copper absorption; must be discontinued and participants must be off zinc for a minimum of 21 days prior to Day 1."
      },
      {
        "name": "Acetaminophen (paracetamol)",
        "role": "Concomitant Medication",
        "description": "Permitted concomitant medication with Investigator approval; maximum 1000 mg/day."
      },
      {
        "name": "Ibuprofen",
        "role": "Concomitant Medication",
        "description": "Permitted concomitant medication with Investigator approval; use with caution; maximum 1200 mg in any 24-hour period."
      }
    ],
    "products": [
      {
        "name": "ALXN1840 tablets (formerly WTX101)",
        "doseForm": "Tablet",
        "strength": "15 mg ALXN1840 (containing 7.8 mg tetrathiomolybdic acid)",
        "manufacturer": "Alexion"
      },
      {
        "name": "Penicillamine",
        "doseForm": null,
        "strength": null,
        "manufacturer": null
      },
      {
        "name": "Trientine",
        "doseForm": null,
        "strength": null,
        "manufacturer": null
      },
      {
        "name": "Zinc therapy",
        "doseForm": null,
        "strength": null,
        "manufacturer": null
      },
      {
        "name": "Acetaminophen (paracetamol)",
        "doseForm": null,
        "strength": null,
        "manufacturer": null
      },
      {
        "name": "Ibuprofen",
        "doseForm": null,
        "strength": null,
        "manufacturer": null
      }
    ],
    "substances": [
      {
        "name": "bis-choline tetrathiomolybdate",
        "description": "Active substance / drug name for ALXN1840; formerly known as WTX101."
      },
      {
        "name": "tetrathiomolybdate (active anion)",
        "description": "Active anion contained in ALXN1840; rapidly binds copper to form tetrathiomolybdate-copper-albumin complex (TPC)."
      },
      {
        "name": "tetrathiomolybdic acid",
        "description": "Amount specified per tablet: 7.8 mg tetrathiomolybdic acid per 15 mg ALXN1840 tablet."
      },
      {
        "name": "penicillamine",
        "description": "Copper-chelating therapy referenced as prior/concomitant WD therapy; discontinued for baseline assessments if used at enrollment."
      },
      {
        "name": "trientine",
        "description": "Copper-chelating therapy referenced as prior/concomitant WD therapy; discontinued for baseline assessments if used at enrollment."
      },
      {
        "name": "zinc",
        "description": "WD therapy; must be discontinued with minimum 21-day washout before Day 1."
      },
      {
        "name": "acetaminophen",
        "description": "Allowed concomitant medication with maximum 1000 mg/day."
      },
      {
        "name": "ibuprofen",
        "description": "Allowed concomitant medication with maximum 1200 mg per 24 hours; caution advised due to CYP2C9 substrate considerations."
      }
    ],
    "administrations": [
      {
        "name": "ALXN1840 15 mg/day (Treatment Period 1)",
        "dose": "15 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Day 1 through Day 28 (approximately 28 days; minimum 4 weeks planned)"
      },
      {
        "name": "ALXN1840 30 mg/day (after titration)",
        "dose": "30 mg (administered as 2 × 15 mg tablets)",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Day 29 through Day 39 (approximately 11 days)"
      },
      {
        "name": "ALXN1840 repeat dosing overall",
        "dose": "15 mg/day or 30 mg/day",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Up to 40 days total dosing per Table 6; participants discontinued from ALXN1840 by their physician at the latest by Day 54 follow-up"
      },
      {
        "name": "ALXN1840 administration conditions (inpatient/CRU)",
        "dose": null,
        "frequency": "once daily (same time every morning)",
        "route": "Oral",
        "duration": "While in CRU during dosing periods (inpatient periods)",
        "additionalInstructions": "Administer after overnight fast (≥10 hours) with 240 mL water; delay meals at least 2 hours after dosing."
      },
      {
        "name": "ALXN1840 administration conditions (outpatient)",
        "dose": null,
        "frequency": "once daily at approximately the same time (±1 hour)",
        "route": "Oral",
        "duration": "During Outpatient Period (Day 9 to Day 23; may be extended up to additional 14 days with Investigator approval)",
        "additionalInstructions": "Take with a glass of water on an empty stomach; delay meals at least 2 hours after dosing; SMS text confirmation of dosing."
      },
      {
        "name": "ALXN1840 dose reduction / rechallenge for ALT elevation",
        "dose": "15 mg every other day (QOD)",
        "frequency": "every other day",
        "route": "Oral",
        "duration": "When ALT returns to <2×ULN (if baseline normal) or <2× increase from baseline (if baseline above reference range) after temporary interruption"
      },
      {
        "name": "ALXN1840 dose reduction for ALT increase >2× baseline or >2×ULN",
        "dose": "Reduce to previous dose level or to 15 mg every other day if on 15 mg once daily",
        "frequency": "every other day (if reduced to 15 mg QOD)",
        "route": "Oral",
        "duration": "Until resolution of abnormality; no further dose increase until resolution"
      },
      {
        "name": "ALXN1840 dose modification for anemia (hemoglobin <8 g/dL without bleeding)",
        "dose": "15 mg every other day (QOD) after interruption",
        "frequency": "every other day",
        "route": "Oral",
        "duration": "After temporary interruption; rechallenge when hemoglobin and other hematology parameters return to baseline"
      },
      {
        "name": "ALXN1840 dose modification for hemoglobin decrease >30% from baseline",
        "dose": "Reduce to previous dose level or to 15 mg every other day if on 15 mg once daily",
        "frequency": "every other day (if reduced to 15 mg QOD)",
        "route": "Oral",
        "duration": "Until resolution of abnormality; no further dose increase until resolution"
      },
      {
        "name": "ALXN1840 dose modification for thrombocytopenia (platelets <30,000/µL)",
        "dose": "15 mg every other day (QOD) after interruption",
        "frequency": "every other day",
        "route": "Oral",
        "duration": "After temporary interruption; rechallenge when platelets and other hematology parameters return to baseline"
      },
      {
        "name": "ALXN1840 dose modification for platelets decrease >30% from baseline (baseline low)",
        "dose": "Reduce to previous dose level or to 15 mg every other day if on 15 mg once daily",
        "frequency": "every other day (if reduced to 15 mg QOD)",
        "route": "Oral",
        "duration": "Until resolution of abnormality; no further dose increase until resolution"
      },
      {
        "name": "ALXN1840 dose modification for neutropenia (neutrophils <1.0 × 10^3/µL)",
        "dose": "15 mg every other day (QOD) after interruption",
        "frequency": "every other day",
        "route": "Oral",
        "duration": "After temporary interruption; rechallenge when neutrophils and other hematology parameters return to baseline"
      },
      {
        "name": "Penicillamine discontinuation for baseline assessment",
        "dose": null,
        "frequency": null,
        "route": null,
        "duration": "If taking at enrollment, discontinue starting Day -4 (approximately 4 days prior to initiating ALXN1840 on Day 1)"
      },
      {
        "name": "Trientine discontinuation for baseline assessment",
        "dose": null,
        "frequency": null,
        "route": null,
        "duration": "If taking at enrollment, discontinue starting Day -4 (approximately 4 days prior to initiating ALXN1840 on Day 1)"
      },
      {
        "name": "Zinc therapy washout",
        "dose": null,
        "frequency": null,
        "route": null,
        "duration": "Must be off zinc therapy for a minimum of 21 days prior to Day 1"
      },
      {
        "name": "Acetaminophen (paracetamol) permitted use",
        "dose": "Up to 1000 mg/day",
        "frequency": null,
        "route": null,
        "duration": "As needed during study with Investigator approval"
      },
      {
        "name": "Ibuprofen permitted use",
        "dose": "Up to 1200 mg per 24-hour period",
        "frequency": null,
        "route": null,
        "duration": "As needed during study with Investigator approval"
      }
    ],
    "devices": []
  }
}